Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Etanercept> ?p ?o. }
Showing items 1 to 71 of
71
with 100 items per page.
- Etanercept abstract "Etanercept (trade names Enbrel and Altebrel) is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.Etanercept is a fusion protein produced by recombinant DNA. It fuses the TNF receptor to the constant end of the IgG1 antibody. First, the developers isolated the DNA sequence that codes the human gene for soluble TNF receptor 2, which is a receptor that binds to tumor necrosis factor-alpha. Second, they isolated the DNA sequence that codes the human gene for the Fc end of immunoglobulin G1 (IgG1). Third, they linked the DNA for TNF receptor 2 to the DNA for IgG1 Fc. Finally, they expressed the linked DNA to produce a protein that links the protein for TNF receptor 2 to the protein for IgG1 Fc.The prototypic fusion protein was first synthesized and shown to be highly active and unusually stable as a modality for blockade of TNF in vivo in the early 1990s by Bruce A. Beutler, an academic researcher then at the University of Texas Southwestern Medical Center at Dallas, and his colleagues. These investigators also patented the protein, selling all rights to its use to Immunex, a biotechnology company that was acquired by Amgen in 2002.It is a large molecule, with a molecular weight of 150 kDa., that binds to TNFα and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNFα.In North America, etanercept is co-marketed by Amgen and Pfizer under the trade name Enbrel in two separate formulations, one in powder form, the other as a pre-mixed liquid. Wyeth was the sole marketer of Enbrel outside North America excluding Japan where Takeda Pharmaceuticals markets the drug.Etanercept is an example of a protein-based drug created using the tools of biotechnology and conceived through an understanding afforded by modern cell biology.".
- Etanercept atcPrefix "L04".
- Etanercept atcSuffix "AB01".
- Etanercept bioavailability "58.0".
- Etanercept casNumber "185243-69-0".
- Etanercept drugbank "DB00005".
- Etanercept fdaUniiCode "OP401G7OJC".
- Etanercept thumbnail Enbrel.jpg?width=300.
- Etanercept wikiPageExternalLink enbrel.pdf.
- Etanercept wikiPageExternalLink Altebrel.html.
- Etanercept wikiPageExternalLink www.enbrel.com.
- Etanercept wikiPageID "732438".
- Etanercept wikiPageRevisionID "606006272".
- Etanercept atcPrefix "L04".
- Etanercept atcSuffix "AB01".
- Etanercept bioavailability "58".
- Etanercept c "2224".
- Etanercept casNumber "185243".
- Etanercept chembl "1201572".
- Etanercept chemspiderid "NA".
- Etanercept drugbank "DB00005".
- Etanercept eliminationHalfLife "475200.0".
- Etanercept h "3475".
- Etanercept hasPhotoCollection Etanercept.
- Etanercept kegg "D00742".
- Etanercept legalStatus "S4 , POM , ℞-only".
- Etanercept metabolism "Reticuloendothelial system".
- Etanercept molecularWeight "51234.9".
- Etanercept n "621".
- Etanercept o "698".
- Etanercept pregnancyCategory "B2 , B".
- Etanercept pubchemsubstance "10099".
- Etanercept routesOfAdministration "Subcutaneous".
- Etanercept s "36".
- Etanercept tradename "Enbrel".
- Etanercept unii "OP401G7OJC".
- Etanercept width "153".
- Etanercept subject Category:Amgen.
- Etanercept subject Category:Immunosuppressants.
- Etanercept subject Category:Recombinant_proteins.
- Etanercept subject Category:TNF_inhibitors.
- Etanercept subject Category:Wyeth.
- Etanercept type Drug.
- Etanercept type DrugProduct.
- Etanercept type FunctionalSubstance.
- Etanercept comment "Etanercept (trade names Enbrel and Altebrel) is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems.".
- Etanercept label "Etanercept".
- Etanercept label "Etanercept".
- Etanercept label "Etanercept".
- Etanercept label "Etanercept".
- Etanercept label "Etanercept".
- Etanercept label "Etanercept".
- Etanercept label "Etanercepte".
- Etanercept label "Étanercept".
- Etanercept label "Этанерцепт".
- Etanercept label "エタネルセプト".
- Etanercept sameAs Etanercept.
- Etanercept sameAs Etanercept.
- Etanercept sameAs Étanercept.
- Etanercept sameAs Etanercept.
- Etanercept sameAs エタネルセプト.
- Etanercept sameAs Etanercept.
- Etanercept sameAs Etanercept.
- Etanercept sameAs Etanercepte.
- Etanercept sameAs m.036lyn.
- Etanercept sameAs Q415343.
- Etanercept sameAs Q415343.
- Etanercept sameAs DB00005.
- Etanercept wasDerivedFrom Etanercept?oldid=606006272.
- Etanercept depiction Enbrel.jpg.
- Etanercept isPrimaryTopicOf Etanercept.